Norasalf (Noradrenaline Tartrate)

Noradrenaline tartrate acts on the sympathetic vascular pathway to support circulatory function in critical care.

• Hypotension: rapidly raises arterial pressure, helping to maintain adequate organ perfusion during acute drops in blood pressure.
• Septic shock: counteracts profound vasodilation by increasing systemic vascular resistance, thereby improving hemodynamic stability in severe infection‑related shock.
• Cardiogenic shock: augments afterload and supports blood pressure, assisting the failing heart to deliver sufficient circulation.

• Noradrenaline tartrate exerts its vasopressor effect by binding to α1‑adrenergic receptors on vascular smooth muscle, triggering phospholipase C activation and intracellular calcium release. This cascade induces potent vasoconstriction, elevating systemic vascular resistance and arterial pressure. At higher concentrations, it also stimulates β1‑adrenergic receptors in the heart, modestly increasing contractility and heart rate, further supporting circulatory output. The overall result is a swift increase in mean arterial pressure, essential for resuscitation.

Noradrenaline tartrate may be associated with a range of adverse reactions, varying from transient to life‑threatening.

Common Side Effects

• Headache: mild to moderate headache during infusion.
• Tremor: transient muscular tremor or shivering.
• Nausea: occasional nausea or vomiting.
• Palpitations: feeling of rapid or irregular heartbeat.

Serious or Rare Side Effects

• Ischemia: reduced blood flow leading to myocardial or peripheral ischemic events.
• Arrhythmias: potentially dangerous heart rhythm disturbances.
• Extravasation: tissue injury if the solution leaks into surrounding tissue.
• Lactic acidosis: rare metabolic disturbance.

When using Noradrenaline tartrate, clinicians should observe specific precautions to minimize risks and ensure therapeutic effectiveness.

• Dose titration: adjust infusion rate to achieve target blood pressure while avoiding excessive vasoconstriction.
• Monitoring: continuously monitor arterial pressure, heart rate, and cardiac rhythm during administration.
• Fluid status: assess intravascular volume to prevent ischemia from excessive vasoconstriction.
• Drug compatibility: avoid mixing with solutions containing calcium or bicarbonate to prevent precipitation.
• Contraindications: do not use in patients with known hypersensitivity to catecholamines.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline tartrate can interact with several agents, altering its hemodynamic effects or safety profile.

Major Interactions (Avoid)

• Beta‑blockers: may blunt the desired increase in cardiac output and cause severe hypotension.
• MAO inhibitors: risk of hypertensive crisis due to excessive catecholamine activity.

Moderate Interactions (Monitor Closely)

• Vasodilators (e.g., nitroglycerin): may require higher noradrenaline doses to maintain pressure.
• Diuretics: can exacerbate hypovolemia, increasing risk of tissue ischemia.
• General anesthetics: may potentiate cardiovascular depression, necessitating careful titration.